Compare General Mills, Inc. (GIS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Sanofi SA — how do they compare? General Mills, Inc. trades at $37.93 (market cap $20.24B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 5.2× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (6.43%). Which is the better fit depends on your goals.
| GIS | SNY | |
|---|---|---|
Market Cap | $20.24B | $104.30B |
Sector | Consumer Staples | Health |
52-Week High | $51.11 | $52.34 |
52-Week Low | $32.17 | $41.33 |
Enterprise Value | $33.73B | $124.19B |
Dividend Yield | 6.43% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $38.21, up 2.55% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings show volatility, beating estimates in Q3 2025 and Q2 2026 but missing in Q4 2025. Revenue has declined from $20.1B in 2023 to $19.5B in 2025, with net income margin turning negative at -0.48% for 2026. The company maintains a dividend and is pursuing cost savings initiatives, while debt-to-asset ratio has risen to 45% in 2025.
Outlook is cautious; the stock offers a low P/E of 9.23 and dividend income, but faces headwinds from weak sales, margin pressure, and high debt. Analyst consensus is mixed with 22% buy, 61% hold ratings. Key risks include competitive pressures and execution of turnaround plans. Investors should weigh valuation appeal against fundamental challenges.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
